SINOVAC and Universitas Gadjah Mada Signed MoU to Deepen R&D Cooperation

Yogyakarta, April 21, 2026 - SINOVAC and Indonesia's Universitas Gadjah Mada, signed a memorandum of understanding in Yogyakarta on April 21, 2026 to deepen R&D cooperation.

Founded in 1949, Universitas Gadjah Mada is one of the oldest, largest, and most prestigious higher education institutions in Indonesia, with a well-established medical education and clinical trial system. The signing of this MOU of cooperation marks a key milestone for SINOVAC to initiate collaborative R&D with local research institutions and enterprises in Indonesia.

Ms. Yaling Hu, the Vice President of R&D, and Mr. Gang Zeng, the Senior Director of the Clinical R&D Center, represented SINOVAC for the signing ceremony. Ms. Hu expressed delight at the visit and the official signing of the cooperation MOU. She remarked that SINOVAC has maintained close cooperation with Indonesia since the COVID-19 pandemic, adding that the signing represents the first step of collaborative research between both sides and is expected to further broaden SINOVAC's collaboration with Indonesia's public health sector.

Speaking at the ceremony, Prof. dr. Ova Emilia, M.Med.Ed., Sp.OG(K), Ph.D., Rector of Universitas Gadjah Mada, noted that Indonesia has a population of over 288 million, and vaccines remain critical to the country's sustainable development amid potential future disease. She stressed the need to continuously deepen bilateral cooperation to drive vaccine development and elevate overall public healthcare services for the Indonesian people.

From left:

Ms. Yuliana Indriati, Director of R&D, PT Bio Farma (Persero)

Prof. dr. Ova Emilia, M.Med.Ed., Sp.OG(K), Ph.D., Rector of Universitas Gadjah Mada

Ms. Yaling Hu, Vice President of SINOVAC

Yuliana Indriati, Director of R&D at PT Bio Farma (Persero), welcomed the partnership between Sinovac and Universitas Gadjah Mada. She voiced optimism that the cooperation would promote joint vaccine R&D in Indonesia, foster local vaccine innovation, production and manufacturing capacity, and pledged full support and preparation for future collaboration.

This R&D cooperation further strengthens SINOVAC's partnership with Indonesia. Going forward, SINOVAC will continue collaborating with local academic and industry partners to advance vaccine innovation and support regional public health development.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.

The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.

SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.

Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.

With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.

For more information, please see the Company’s website at www.sinovac.com.